Heymach, J., Hanrahan, E., Mann, H., Langmuir, P., Natale, R., Johnson, B., . . . Ryan, A. (2008). Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.
Цитирование в стиле Чикаго (17-е изд.)Heymach, J., E. Hanrahan, H. Mann, P. Langmuir, R. Natale, B. Johnson, R. Herbst, и A. Ryan. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
Цитирование MLA (9-е изд.)Heymach, J., et al. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.